Shots:

• The P-III CREDIT-2 study evaluates the efficacy and safety of IBI306 vs PBO in 148 Chinese patients with HeFH- prior treated with statins and ezetimibe. The study provides high-quality clinical evidence for patients with the same indication
• The study met its 1EPs i.e.- reduction in the LDL-C levels @12wks. of continuous treatment & demonstrated a safety profile similar to the reported safety profiles of other marketed PCSK-9 inhibitors
• IBI306 is an lgG2 mAb that binds to PCSK-9. Additionally- P-I & IIa study for IBI306 demonstrated good efficacy with a favorable safety profile to treat patients with hypercholesterolemia

   Ref: PR Newswire | Image: Innovent